Acute bilateral trigeminal neuropathy associated with nervous system lymphosarcoma in a dog

2000 ◽  
Vol 36 (1) ◽  
pp. 57-61 ◽  
Author(s):  
AM Pfaff ◽  
PA March ◽  
C Fishman
Keyword(s):  
Nervous System ◽  
Histopathological Examination ◽  
Clinical Signs ◽  
Neoplastic Cell ◽  
Brain Parenchyma ◽  
Spinal Root ◽  
Trigeminal Neuropathy ◽  
Neoplastic Lymphocytes ◽  
Multicentric Lymphoma ◽  
Masseter Muscles

A nine-year-old dog presented with clinical signs consistent with bilateral trigeminal neuropathy. Multicentric lymphoma was diagnosed, and neoplastic lymphocytes were identified in the cerebrospinal fluid. Electromyography revealed spontaneous activity in temporal and masseter muscles. Histopathological examination demonstrated neoplastic cell invasion of temporal and masseter myofibers and of multiple peripheral nerves, including the trigeminal nerve. Central nervous system pathology consisted primarily of spinal root and leptomeningeal lymphoid cell infiltration with relative sparing of spinal cord and brain parenchyma.

scholarly journals Multicentric lymphoma with metastasis in the central nervous system in a dog

2005 ◽  
Vol 57 (3) ◽  
pp. 307-311 ◽  
Author(s):  
K.P. Aptekmann ◽  
C.E. Okamoto ◽  
K.C.H. Campos ◽  
R.K. Takahira
Keyword(s):  
Central Nervous System ◽  
Cell Invasion ◽  
Histopathological Examination ◽  
Neoplastic Cell ◽  
Neurological Deficits ◽  
Immunohistochemical Examination ◽  
The Central Nervous System ◽  
Neoplastic Lymphocytes ◽  
Generalized Lymphadenopathy ◽  
Multicentric Lymphoma

Multicentric lymphoma was diagnosed in a two-year-old dog with respiratory distress, dysorexia, abdominal enlargement and generalized lymphadenopathy. Immunohistochemical examination showed T-cell origin with CD3+ e CD79- expression. After five weeks, progressive neurological deficits and neoplastic lymphocytes were identified in the cerebrospinal fluid. Histopathological examination showed neoplastic cell invasion in the spleen, lymph nodes, cerebrum and cerebellum.

scholarly journals Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19

2021 ◽  
Author(s):  
Anne Hege Aamodt ◽  
Einar August Høgestøl ◽  
Trine Haug Popperud ◽  
Jan Cato Holter ◽  
Anne Ma Dyrhol-Riise ◽  
...  
Keyword(s):  
Nervous System ◽  
Single Molecule ◽  
Linear Models ◽  
Clinical Signs ◽  
Repeated Measurements ◽  
Cns Injury ◽  
Serum Concentrations ◽  
Blood Biomarkers ◽  
Neurofilament Light Chain ◽  
Neurofilament Light

Abstract Objective To test the hypotheses that blood biomarkers for nervous system injury, serum concentrations of neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAp) can serve as biomarkers for disease severity in COVID-19 patients. Methods Forty-seven inpatients with confirmed COVID-19 had blood samples drawn on admission for assessing serum biomarkers of CNS injury by Single molecule array (Simoa), NfL and GFAp. Concentrations of NfL and GFAp were analyzed in relation to symptoms, clinical signs, inflammatory biomarkers and clinical outcomes. We used multivariate linear models to test for differences in biomarker concentrations in the subgroups, accounting for confounding effects. Results In total, 21% (n = 10) of the patients were admitted to an intensive care unit, and the overall mortality rate was 13% (n = 6). Non-survivors had higher serum concentrations of NfL (p < 0.001) upon admission than patients who were discharged alive both in adjusted analyses (p = 2.6 × 10–7) and unadjusted analyses (p = 0.001). The concentrations of NfL in non-survivors increased over repeated measurements; whereas, the concentrations in survivors were stable. The GFAp concentration was also significantly higher in non-survivors than survivors (p = 0.02). Conclusion Increased concentrations of NfL and GFAp in COVID-19 patients on admission may indicate increased mortality risk. Measurement of blood biomarkers for nervous system injury can be useful to detect and monitor CNS injury in COVID-19.

Incidence and treatment of feline renal lymphoma: 27 cases

2021 ◽  
pp. 1098612X2098436
Author(s):  
Ashlyn G Williams ◽  
Ann E Hohenhaus ◽  
Kenneth E Lamb
Keyword(s):  
Median Survival ◽  
Clinical Stage ◽  
Large Population ◽  
Clinical Signs ◽  
Treatment Protocol ◽  
Central Nervous System Involvement ◽  
Data Set ◽  
Hematopoietic Malignancy ◽  
Renal Lymphoma ◽  
Multicentric Lymphoma

Objectives Lymphoma is the most common feline hematopoietic malignancy. Incidence of renal lymphoma has not been reported as a subset of a large population of feline lymphoma cases. Previous studies have reported renal lymphoma as both a singular entity as well as a component of multicentric disease. The clinical presentation, diagnostic evaluation, therapy and outcomes related to renal lymphoma have not been reported since Mooney et al in 1987. This retrospective study aimed to describe the incidence of renal lymphoma, clinical signs, treatment and survival. Methods Using a database of cats diagnosed with lymphoma between January 2008 and October 2017, cats with renal lymphoma were selected for further analysis. Cases were retrospectively staged according to Mooney et al (1987) and Gabor et al (1998). Data collected included age, clinical signs, clinicopathologic data, diagnostic imaging findings, lymphoma diagnostic method(s), treatment protocol(s) and survival time. Analyses comparing median survival based on therapy administered, renal lymphoma vs multicentric lymphoma, central nervous system involvement, presence of azotemia, anemia and International Renal Interest Society (IRIS) stage at diagnosis were performed. Results From a population of 740 cats with lymphoma, 27 cats had renal lymphoma (incidence, 3.6%), and 14 of those cats had multicentric lymphoma. Fewer stage IV and V cases were identified in this data set compared with Mooney et al; however, not all cats were completely staged. Median survival (range) for cats receiving corticosteroids alone compared with those receiving an L-CHOP (L-asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisolone)-based protocol was 50 days (20–1027 days) in the corticosteroid group and 203 days (44–2364 days) for the L-CHOP group ( P = 0.753) for cats that died secondary to lymphoma. Conclusions and relevance Neither clinical stage nor other factors were predictive of survival. Prospective studies are required to determine the optimal chemotherapy protocol.

Multiple myeloma manifesting as an intraventricular brain tumor

2009 ◽  
Vol 110 (4) ◽  
pp. 737-739 ◽  
Author(s):  
Joo-Hun David Eum ◽  
Astrid Jeibmann ◽  
Werner Wiesmann ◽  
Werner Paulus ◽  
Heinrich Ebel
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Myeloma ◽  
Brain Tumor ◽  
Magnetic Resonance ◽  
Lateral Ventricle ◽  
Histopathological Examination ◽  
Brain Parenchyma ◽  
Resonance Imaging

Primary intracerebral manifestation of multiple myeloma is rare and usually arises from the meninges or brain parenchyma. The authors present a case of multiple myeloma primarily manifesting within the lateral ventricle. A 67-year-old man was admitted with headache accompanied by slowly progressing right hemiparesis. Magnetic resonance imaging showed a large homogeneous contrast-enhancing intraventricular midline mass and hydrocephalus. The tumor was completely resected, and histopathological examination revealed plasmacytoma. After postoperative radio- and chemotherapy, vertebral osteolysis was detected as a secondary manifestation of multiple myeloma.

Lyme Disease: Acute Focal Meningoencephalitis in a Child

PEDIATRICS ◽  
1988 ◽  
Vol 82 (6) ◽  
pp. 931-934
Author(s):  
HENRY M. FEDER ◽  
EDWIN L. ZALNERAITIS ◽  
LOUIS REIK
Keyword(s):  
Nervous System ◽  
Case Report ◽  
Lyme Disease ◽  
Signs And Symptoms ◽  
Brain Parenchyma ◽  
Tick Bite ◽  
System Involvement ◽  
History Of ◽  
Csf Pleocytosis ◽  
The Brain

Nervous system involvement in Lyme disease was originally described as meningitis, cranial neuritis, and radiculoneuritis,1-3 but Lyme disease can also involve the brain parenchyma. We describe a child whose first manifestation of Lyme disease was an acute, focal meningoencephalitis with signs and symptoms such as fever, headache, slurred speech, hemiparesis, seizure, and CSF pleocytosis. CASE REPORT A 7-year-old boy was hospitalized Aug 27, 1985, because of hemiparesis. Six weeks prior to admission he had vacationed at Old Lyme, CT. There was no history of rash or tick bite. He had been well until eight hours prior to admission when fever and headache developed.

scholarly journals Invasive nasal histiocytic sarcoma as a cause of temporal lobe epilepsy in a cat

2018 ◽  
Vol 4 (2) ◽  
pp. 205511691881117 ◽  
Author(s):  
Koen M Santifort ◽  
Ben Jurgens ◽  
Guy CM Grinwis ◽  
Ingrid Gielen ◽  
Björn P Meij ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Temporal Lobe Epilepsy ◽  
Temporal Lobe ◽  
Histopathological Examination ◽  
Clinical Signs ◽  
Olfactory Neuroblastoma ◽  
Histiocytic Sarcoma ◽  
Cribriform Plate ◽  
Differential Diagnoses ◽  
Tissue Mass

Case summary A 10-year-old neutered female domestic shorthair cat was presented with an acute onset of neurological signs suggestive of a right-sided forebrain lesion, temporal lobe epilepsy and generalised seizure activity. MRI of the head revealed an expansile soft tissue mass in the caudal nasal passages (both sides but predominantly right-sided) involving the ethmoid bone and extending through the cribriform plate into the cranial vault affecting predominantly the right frontal lobe and temporal lobe. Histopathological examination of the tumour revealed a histiocytic sarcoma. Relevance and novel information This is the first report of a cat with clinical signs of temporal lobe epilepsy due to an invasive, histiocytic sarcoma. Histiocytic sarcoma, although rare, should be included in the list of differential diagnoses for soft tissue masses extending through the cribriform plate. Other differential diagnoses are primary nasal neoplasia (eg, adenocarcinoma, squamous cell carcinoma, chondrosarcoma and other types of sarcomas), lymphoma and olfactory neuroblastoma. Temporal lobe epilepsy in cats can be the consequence of primary pathology of temporal lobe structures, or it can be a consequence of pathology with an effect on these structures (eg, mass effect or disruption of interconnecting neuronal pathways).

scholarly journals Assessment of Acute Oral and Dermal Toxicity of 2 Ethyl-Carbamates with Activity againstRhipicephalus microplusin Rats

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
María Guadalupe Prado-Ochoa ◽  
Ricardo Alfonso Gutiérrez-Amezquita ◽  
Víctor Hugo Abrego-Reyes ◽  
Ana María Velázquez-Sánchez ◽  
Marco Antonio Muñoz-Guzmán ◽  
...  
Keyword(s):  
Nervous System ◽  
Maximum Dose ◽  
Clinical Signs ◽  
Clinical Manifestations ◽  
Dermal Toxicity ◽  
Severe Damage ◽  
Coagulative Necrosis ◽  
Gamma Glutamyltransferase ◽  
Oral Doses ◽  
Dermal Application

The acute oral and dermal toxicity of two new ethyl-carbamates (ethyl-4-bromophenyl-carbamate and ethyl-4-chlorophenyl-carbamate) with ixodicide activity was determined in rats. The oral LD50of each carbamate was 300 to 2000 mg/kg, and the dermal LD50of each carbamate was >5000 mg/kg. Clinically, the surviving rats that had received oral doses of each carbamate showed decreased weight gain (P<0.05) and had slight nervous system manifestations. These clinical signs were evident from the 300 mg/kg dose and were reversible, whereas the 2000 mg/kg dose caused severe damage and either caused their death or was motive for euthanasia. At necropsy, these rats had dilated stomachs and cecums with diffuse congestion, as well as moderate congestion of the liver. Histologically, the liver showed slight degenerative lesions, binucleated hepatocytes, focal coagulative necrosis, and congestion areas; the severity of the lesions increased with dosage. Furthermore, an slight increase in gamma-glutamyltransferase, lactate dehydrogenase, and creatinine was observed in the plasma. The dermal application of the maximum dose (5000 mg/kg) of each carbamate did not cause clinical manifestations or liver and skin alterations. This finding demonstrates that the carbamates under study have a low oral hazard and low acute dermal toxicity.

Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism

1972 ◽  
Vol 2 (4) ◽  
pp. 406-413 ◽  
Author(s):  
R. H. S. Mindham ◽  
R. Gaind ◽  
B. H. Anstee ◽  
Lorna Rimmer
Keyword(s):  
Nervous System ◽  
Practical Importance ◽  
Clinical Signs ◽  
Drug Induced ◽  
Double Blind ◽  
Fluphenazine Decanoate ◽  
Cholinergic Drugs ◽  
Blind Comparison ◽  
Pharmacologically Active ◽  
Active Substances

SynopsisA double-blind comparison was made of the effects of amantadine hydrochloride, orphenadrine hydrochloride, and placebo in the control of the effects on the extrapyramidal nervous system of fluphenazine decanoate. Patients were assessed with regard to the main symptoms of Parkinsonism, the leading clinical signs, performance in walking, writing and squeezing, changes in mood, and unwanted effects of medication. Neither of the pharmacologically active substances was superior to placebo. Attention is drawn to the paucity of evidence for the effectiveness of anti-cholinergic drugs in both Parkinson's disease and in drug-induced Parkinsonism. The special difficulties in performing trials of substances used in relieving the unwanted effects of other drugs are discussed in relationship to defects in methodology in both this and earlier trials. The findings of the present study are not conclusive but show a clear need for further research in this field. The possible theoretical and practical importance of such research is discussed.

scholarly journals Negative MRI findings in a case of degenerative myelopathy in a dog : clinical communication

2009 ◽  
Vol 80 (4) ◽  
Author(s):  
M. Okada ◽  
M. Kitagawa ◽  
K. Kanayama ◽  
H. Yamamura ◽  
T. Sakai
Keyword(s):  
Magnetic Resonance Imaging ◽  
Histopathological Examination ◽  
Clinical Signs ◽  
Resonance Imaging ◽  
Mri Findings ◽  
Clinical Communication ◽  
Bladder Control ◽  
Blood Tests ◽  
Degenerative Myelopathy ◽  
Magnetic Resonance Imaging Mri

An 11-year-old male Rough collie was submitted with paraparesis, but did not respond to medical treatment. Clinical signs worsened and the dog displayed paralysis, inability to stand and loss of voluntary bladder control, whereupon magnetic resonance imaging (MRI) was performed. No significant abnormalities were identified from MRI, blood tests, cerebrospinal fluid tests or radiography. After MRI, the dog developed dyspnoea and died. Autopsy and subsequent histopathological examination led to a diagnosis of degenerative myelopathy.

Sign in / Sign up

Export Citation Format

Share Document